Pfizer: Hong Kong to resume BioNTech-Pfizer vaccine after packaging defects

Apr 01 2021 04:23 PM
Pfizer: Hong Kong to resume BioNTech-Pfizer vaccine after packaging defects

Hong Kong will continue administering the Covid19 vaccine developed by Pfizer and BioNTech on Monday following a 12-day suspension over packaging defects detected in one batch, officials said.  Further, additional  3,00,000 doses of the vaccine are expected to arrive in Hong Kong on Friday, Civil Service Secretary Patrick Nip said Thursday.

 “BioNTech believes that the efficacy of the vaccine has not been affected, so members of the public who have taken the BioNTech vaccine need not be worried,” said Constance Chan, Hong Kong's director of health. Health officials said an investigation by BioNTech found no safety issues in the batch with packaging defects for some vials, as well as in a separate, unused batch of the vaccine. Random checks will also be stepped up to ensure that vaccine packaging is safe, she said.

Residents who missed their vaccine appointments due to the suspension will be rescheduled. Those waiting to receive their second doses will have appointments within the first few days of the resumption, officials said.

Apart from the Pfizer vaccine, Hong Kong residents have the option to receive Chinese-made Sinovac shots, although acceptance of that vaccine has fallen after reports that several people with chronic illnesses died after getting it.

The packaging defects included loose caps and leakage from some bottles. Prior to the suspension, about 151,000 people had received the Pfizer vaccine in the city.

Hong Kong officials say the deaths were not directly linked to the vaccine, but widespread distrust of the government and of Beijing means fewer residents are willing to be inoculated with the Sinovac shots.

Italy grants Open Arms, permission to bring rescued migrants to Sicily

FIFA Women’s World Cup organizers revealed 9 host cities name

Portugal upgrades mandatory use of masks in public spaces until June 13